Michael J. La Barre is SVP, CHIEF TECHNICAL OFFICER of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 173,756 shares of HALO, which is worth approximately $10.3 Million. The most recent transaction as insider was on Aug 27, 2024, when has been sold 5,580 shares (Common Stock) at a price of $18.41 per share, resulting in proceeds of $102,727. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 174K
3.32% 3M change
14.38% 12M change
Total Value Held $10.3 Million

Michael J. LaBarre Transaction History

Date Transaction Value Shares Traded Shares Held Form
Aug 27 2024
BUY
Exercise of conversion of derivative security
$102,727 $18.41 p/Share
5,580 Added 3.11%
173,756 Common Stock
Aug 21 2024
SELL
Open market or private sale
$620,400 $62.04 p/Share
10,000 Reduced 5.61%
168,176 Common Stock
Aug 21 2024
BUY
Exercise of conversion of derivative security
$166,500 $16.65 p/Share
10,000 Added 5.31%
178,176 Common Stock
Aug 20 2024
SELL
Open market or private sale
$610,500 $61.05 p/Share
10,000 Reduced 5.61%
168,176 Common Stock
Aug 20 2024
BUY
Exercise of conversion of derivative security
$166,500 $16.65 p/Share
10,000 Added 5.31%
178,176 Common Stock
Jul 24 2024
SELL
Open market or private sale
$551,200 $55.12 p/Share
10,000 Reduced 5.61%
168,176 Common Stock
Jul 24 2024
BUY
Exercise of conversion of derivative security
$123,800 $12.38 p/Share
10,000 Added 5.31%
178,176 Common Stock
Jul 23 2024
SELL
Open market or private sale
$548,700 $54.87 p/Share
10,000 Reduced 5.61%
168,176 Common Stock
Jul 23 2024
BUY
Exercise of conversion of derivative security
$81,100 $8.11 p/Share
10,000 Added 5.31%
178,176 Common Stock
Jun 18 2024
SELL
Open market or private sale
$494,300 $49.43 p/Share
10,000 Reduced 5.61%
168,176 Common Stock
Jun 18 2024
BUY
Exercise of conversion of derivative security
$81,100 $8.11 p/Share
10,000 Added 5.31%
178,176 Common Stock
May 22 2024
SELL
Open market or private sale
$453,800 $45.38 p/Share
10,000 Reduced 5.61%
168,176 Common Stock
May 22 2024
BUY
Exercise of conversion of derivative security
$81,100 $8.11 p/Share
10,000 Added 5.31%
178,176 Common Stock
May 21 2024
SELL
Open market or private sale
$451,599 $45.16 p/Share
10,000 Reduced 5.61%
168,176 Common Stock
May 21 2024
BUY
Exercise of conversion of derivative security
$81,100 $8.11 p/Share
10,000 Added 5.31%
178,176 Common Stock
Apr 17 2024
SELL
Open market or private sale
$384,900 $38.49 p/Share
10,000 Reduced 5.61%
168,176 Common Stock
Apr 17 2024
BUY
Exercise of conversion of derivative security
$81,100 $8.11 p/Share
10,000 Added 5.31%
178,176 Common Stock
Apr 16 2024
SELL
Open market or private sale
$383,500 $38.35 p/Share
10,000 Reduced 5.61%
168,176 Common Stock
Apr 16 2024
BUY
Exercise of conversion of derivative security
$81,100 $8.11 p/Share
10,000 Added 5.31%
178,176 Common Stock
Mar 26 2024
BUY
Exercise of conversion of derivative security
$143,133 $12.32 p/Share
11,618 Added 6.46%
168,176 Common Stock
Mar 13 2024
SELL
Open market or private sale
$422,700 $42.27 p/Share
10,000 Reduced 6.0%
156,558 Common Stock
Mar 13 2024
BUY
Exercise of conversion of derivative security
$100,900 $10.09 p/Share
10,000 Added 5.66%
166,558 Common Stock
Mar 12 2024
SELL
Open market or private sale
$416,400 $41.64 p/Share
10,000 Reduced 6.0%
156,558 Common Stock
Mar 12 2024
BUY
Exercise of conversion of derivative security
$120,700 $12.07 p/Share
10,000 Added 5.66%
166,558 Common Stock
Feb 28 2024
SELL
Open market or private sale
$395,500 $39.55 p/Share
10,000 Reduced 6.0%
156,558 Common Stock
MJL

Michael J. La Barre

SVP, CHIEF TECHNICAL OFFICER
San Diego, CA

Track Institutional and Insider Activities on HALO

Follow HALOZYME THERAPEUTICS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO